FIELD: transplantology.
SUBSTANCE: invention discloses pharmaceutical compositions containing substance effective as modulators of biological activity "induced by activation of lymphocytic immunomodulating molecule (AILIM)" (known also as "induced common stimulator (ICOS)"), in particular modulating transduction of AILIM-mediated signal.
EFFECT: achieved suppression, treatment, or prevention of rejection of transplant arising in case of transplantation of organ, a part thereof or tissue.
11 cl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED MONOCLONAL ANTIBODY RAISED AGAINST AILIM, CO-STIMULATING MOLECULE FOR SIGNAL TRANSFER AND ITS PHARMACEUTICAL APPLYING | 2001 |
|
RU2262511C2 |
| PHARMACEUTICAL COMPOSITION FOR IMMUNE DISEASE TREATMENT | 2000 |
|
RU2203682C2 |
| AGENTS FOR TREATMENT OF INFLAMMATORY INTESTINAL DISEASES | 2002 |
|
RU2281118C2 |
| METHOD FOR OBTAINING TRANSGENIC ANIMAL | 1990 |
|
RU2252533C2 |
| METHOD FOR TRANSPLANTATION OF ANIMAL CELL, TISSUE OR ORGAN FOR A RECIPIENT AND PREPARATION FOR ITS IMPLEMENTATION | 1990 |
|
RU2195956C2 |
| RECOMBINANT ANTIBODY AGAINST CD4 FOR HUMAN THERAPY | 1996 |
|
RU2232773C2 |
| CHRONIC REJECTION INHIBITOR | 2008 |
|
RU2450829C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
